Data / Form D filings / SOLAZYME INC
SOLAZYME INC: Form D filings
SOLAZYME INC, a biotechnology company in South San Francisco, CA, filed 3 Form D notices with the SEC between 2010 and 2016. The latest, on March 24, 2016, reports $28.8 million sold of a $28.8 million offering to 18 investors.
Find out what SOLAZYME INC does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 225 Gateway Blvd., South San Francisco, CA, 94080
- Phone
- (650) 780-4777
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $25,000,001 - $100,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1311230
The full lists. Form D filings in California: 5,891 rows, $138.91, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 24, 2016 | New notice | $28,750,000 | $28,750,000 | $0 | 18 | Mar 10, 2016 | sec.gov |
| Sep 8, 2010 | Amendment | $59,999,825 | $59,999,825 | $0 | 22 | May 19, 2010 | sec.gov |
| Aug 9, 2010 | New notice | Indefinite | $51,549,873 | Indefinite | 17 | May 19, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Paul T. Quinlan | Executive Officer | |
| Ian T. Clark | Director | |
| Jonathan S. Wolfson | Executive Officer, Director | |
| Irene Chang Britt | Director | |
| Peter J. Licari | Executive Officer | |
| James R. Craigie | Director | |
| Gary M. Pfeiffer | Director | |
| Michael V. Arbige | Director | |
| Tyler W. Painter | Executive Officer | |
| Jerry R. Fiddler | Director |
Other biotechnology companies in California that filed recently
- CARI Health, Inc. $280,000 · Nov 6, 2026
- Ausel, Inc. $120,000 · Nov 4, 2026
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
- Tempest Therapeutics, Inc. $7.5 million · Oct 14, 2026
- Lionheart Health, Inc. $387,500 · Oct 7, 2026
- Rakuten Medical, Inc. $9 million · Oct 6, 2026
- Zonaliz, Inc. $2.5 million · Oct 5, 2026
- Altay Therapeutics, Inc. $15.7 million · Oct 2, 2026
- Sialia Therapeutics, Inc. $1.5 million · Sep 29, 2026
- Vetmab Biosciences, Inc. $11.4 million · Sep 29, 2026
Every Form D from the week of Mar 21, 2016 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what SOLAZYME INC reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.